This review concluded that there was insufficient evidence of the efficacy of traditional Chinese medicine in the treatment of Helicobacter pylori and although traditional Chinese medicine may be safer than triple therapy, it should not be recommended as monotherapy. Given the poor quality of the included studies, the authors' conclusions and recommendations for practice seem appropriate and reliable.
Authors' objectives
To evaluate the efficacy and safety of traditional Chinese medicine for the treatment of Helicobacter pylori (H. pylori).
Searching MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Weipu and Wanfang databases were searched without language restrictions up to 2008; search terms were reported. Bibliographies of included trials and conference abstracts were searched.
Study selection
Randomised controlled trials (RCTs) that compared single herb, formulae or Chinese medicine products to treatments in patients with chronic or remnant gastritis, peptic ulcers or gastro-oesophageal reflux and diagnosed with H. pylori were eligible for inclusion. Both treatment and diagnosis of H. pylori had to be in accordance with the Consensus Report. Patients with bleeding ulcer or gastric cancer were excluded. Outcomes of interest were H. pylori eradication rates as defined by the Consensus Report and adverse events.
The Chinese medicines that were evaluated varied widely. Duration of treatment ranged from seven to 60 days. All comparators were triple therapies, with varying combinations of proton pump inhibitors, antacids and antibiotics; treatment duration was seven, 10 or 14 days. Where reported, participants' age ranged from 16 to 85 years and 48% to 79% were male.
Two independent reviewers screened studies for inclusion; disagreements were resolved by discussion or a third reviewer.
Assessment of study quality
Trial quality was assessed using the Jadad score; allocation concealment was also assessed. The number of authors who performed the quality assessment was not reported.
Data extraction
The numbers of patient in whom H. pylori was eradicated or who experienced an adverse event were extracted and relative risks (RR) with 95% confidence intervals (CI) calculated.
The number of authors who extracted data was not reported.
Methods of synthesis
Heterogeneity was assessed using the X 2 and I 2 statistics. Where I 2 was 0 a fixed-effect model was used, where I 2 was less than 50% a random-effects model was used; a pooled estimate was not calculated where I 2 was greater than 50%. As heterogeneity was more than 50%, average incidence rates were calculated and studies were combined in a narrative synthesis. Publication bias was assessed using a funnel plot. 
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